Literature DB >> 2894960

Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat.

D H Marchand1, R P Remmel, M M Abdel-Monem.   

Abstract

gamma-Glutamyl-beta-(S-tetrahydrothiophenium)alanyl-glycine, the glutathione-sulfonium conjugate of busulfan and 1,4-diiodobutane, was identified in the bile of rats following intravenous administration of equimolar doses of either compound. The glutathione-sulfonium conjugate was synthesized from 1-bromo-4-chlorobutane and characterized by 1H and 13C NMR and FAB/MS. An HPLC method was developed to identify the conjugate from rat bile by pre-column fluorescent derivatization with o-phthalaldehyde. The biliary excretion of cyclic sulfonium conjugates was quantitated indirectly by measuring the release of tetrahydrothiophene (THT) after treatment of the bile with base. THT release was quantitative and was measured by gas chromatography. With busulfan, peak biliary concentrations of THT-releasing metabolite(s) were reached after 90 min and 26% of the dose of busulfan was recovered in the bile after 8 hr. When diiodobutane was administered, 21% of the dose was recovered, and the peak concentration was reached in 30 min. The decline in THT releasing metabolite(s) was more rapid with 1,4-diiodobutane, and THT was no longer measurable after 3.5 hr compared to 7.5 hr after busulfan administration. These data confirm that busulfan and other 1,4-disubstituted butanes are conjugated with glutathione in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894960

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

Review 1.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.

Authors:  Kyoung-Ah Kim; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2010-03-20       Impact factor: 2.953

3.  Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.

Authors:  Islam R Younis; Meenal Elliott; Cody J Peer; Arthur J L Cooper; John T Pinto; Gregory W Konat; Michal Kraszpulski; William P Petros; Patrick S Callery
Journal:  J Pharmacol Exp Ther       Date:  2008-09-12       Impact factor: 4.030

4.  Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog.

Authors:  J I Brodfuehrer; T J Wilke; D H Kinder; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.

Authors:  H P Bhagwatwar; S Phadungpojna; D S Chow; B S Andersson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 6.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.